GRAND RAPIDS, MICHIGAN / ACCESS Newswire / September 25, 2025 / As the back-to-school season begins, the strain of transition extends beyond students to parents, professors, and staff. Limited campus resources often mean long waits for ADHD, anxiety, or depression evaluations, delaying care and harming academic performance.

Mentavi Health‘s clinically validated, asynchronous Diagnostic Evaluation – the first online assessment for adult ADHD validated against the current standard of care and now peer-reviewed and published in the Journal of Clinical Psychiatry – reduces waits from weeks to days, giving students timely answers when they matter most.

“Early identification and treatment of ADHD and related mental health conditions is crucial for improved clinical outcomes,” said Mentavi Health Chief Medical Officer Barry K. Herman, M.D., MMM. Timely diagnosis allows students to access the right accommodations and support to stay on track academically and personally.

Mentavi now serves more than a dozen higher-education institutions nationwide and has completed over 20,000 student evaluations, demonstrating both the scalability of its services and the value institutions place on timely, validated mental health support. Publication in the Journal of Clinical Psychiatry, one of the field’s leading peer-reviewed journals, further underscores Mentavi’s commitment to scientific rigor and expanding evidence-based access to care.

“For many of our students, the greatest challenge isn’t the classroom itself but the invisible barriers that prevent them from accessing the accommodations they are entitled to under federal law,” said Jana Garnett, DSPS Coordinator/Director at Santa Barbara City College. “By making professional diagnoses accessible and affordable, Mentavi gives our students a pathway to the support they need to persist and succeed in college.”

Efficient and affordable support

Students can complete the Diagnostic Evaluation independently in one to two hours. Each evaluation is reviewed by a licensed, doctorate-level clinician – not automated AI – with results delivered within five days. Students may then share their results with the appropriate offices at their college or university to discuss accommodations or treatment options when warranted.

Alternatively, in over 40 states, students can choose to meet with a Mentavi clinician to explore therapy, medical treatment, or coaching. This flexibility allows institutions to either keep students within their own health systems or to expand support through Mentavi’s nationwide network. At $189 per evaluation, Mentavi’s service is also far more affordable than traditional in-clinic assessments.

Improved student outcomes and institutional reputation

Early and accurate diagnosis empowers students to understand their challenges, access the right support, and adopt strategies that improve performance, strengthen retention, and build adaptability for life after graduation. For institutions, providing timely answers demonstrates a commitment to student well-being and reduces the risk of students falling behind.

“With national discussions underway about stimulant and non-stimulant treatments, and with increasing state-level scrutiny of AI in healthcare, Mentavi stands out by combining validated assessments with a human-centered model: every evaluation is reviewed by a licensed clinician, ensuring accuracy and accountability,” said Keith Brophy, CEO of Mentavi Health.

“Our mission has always been to make clinically validated mental health care accessible and affordable. As the new school year begins, higher-education institutions seek proven ways to support their students while managing limited resources. By partnering with Mentavi, colleges and universities can offer timely, evidence-based diagnosis and care as appropriate that reduces the stress families, faculty, and staff feel during this critical transition period.”

For more information, visit Mentavi Health or ADHD Online. The Mentavi Health Diagnostic Evaluation is clinically validated for the diagnosis of ADHD in adults. Study results were published in the Journal of Clinical Psychiatry on September 8, 2025 (J Clin Psychiatry 2025;86(3):25m15846; doi:10.4088/JCP.25m15846).

About Mentavi Health and ADHD Online

Established as ADHD Online in 2018, Mentavi Health has evolved to encompass a broader range of mental health services. With the mission to make high-quality ADHD assessments accessible to all, Mentavi has grown to address not only ADHD but also the most common related mental health conditions. The nationwide Mentavi Mental Health Diagnostic Evaluation and various treatment options showcase the company’s commitment to providing comprehensive, accessible, compliant online mental health care. For more information, visit mentavi.com.

Media contact:

Tim Cox, ZingPR for Mentavi Health tim@zingpr.com

Clinically validated ADHD diagnostic model positions Mentavi as a benchmark for trustworthy digital health solutions.

GRAND RAPIDS, Mich., September 15, 2025 (Newswire.com) – Mentavi Health will take a prominent role in Tech Week Grand Rapids (September 15-19, 2025), where CEO and Tech Week co-chair Keith Brophy will share insights at the intersection of health care and technology, drawing on Mentavi’s peer-reviewed, clinically validated digital diagnostic solutions as an example of how innovation can set new standards for trust in digital health.

Mentavi Health, founded in 2018, provides a broad spectrum of online services, from mental wellness checks to diagnosis and treatment. Mentavi is nationally recognized as an innovator in online mental health diagnosis and treatment.

Brophy’s leadership across multiple Tech Week events-including chairing the kickoff party, joining a digital health panel, and engaging with the VC Insights & Innovation Showcase-underscores Mentavi’s role as both a West Michigan success story and a national leader in validated digital health. Tech Week is expected to draw more than 16,000 attendees. 

Tech Week provides a platform to highlight Mentavi’s growth from its West Michigan roots to its recognition as a national benchmark for validated online mental health diagnostics.* Notably, Mentavi presented data at the 10th World Congress on ADHD in May and published a peer-reviewed validation study in the Journal of Clinical Psychiatry (September 2025), documenting the accuracy of its proprietary online assessment.

Beyond Mentavi, Brophy is widely recognized as a leader in Michigan’s technology community, with a career spanning more than 25 years at the intersection of AI, healthcare, and entrepreneurship. His thought leadership has been featured in regional media and industry forums, where he has highlighted both the promise of technology and the importance of the human side of innovation. Brophy has underscored Mentavi Health’s commitment to deliver diagnosis and treatment with human psychologists, physicians, and coaches adhering to rigorous national clinical standards, with strong guardrails against AI providing any kind of patient clinical advice.

“Our approach has always been about doing this the right way-validated, clinician-reviewed, and built to earn trust from patients, partners, and regulators alike,” Brophy said. “At a time when credibility is the deciding factor in digital health, Tech Week is a meaningful place to share that story, both because of its focus on innovation and because West Michigan is where we’re proving that trustworthy digital health can thrive, and where I’ve dedicated much of my career to building a vibrant tech community.”

Tech Week Grand Rapids, where “Capital Meets Innovation,” will feature more than 50 events on innovation, investment, and entrepreneurship. Steve Wozniak, co-founder of Apple, is the keynote speaker. The conference highlights Grand Rapids’ growing reputation as a technology hub, with Mentavi featured among the innovators helping to shape the future of digital health.

“At Tech Week GR we’re showing that credible innovation isn’t just good medicine-it’s good growth. Mentavi wins business by setting a higher bar for trust,” said Corey Hart, senior director of business growth at Mentavi Health.

About 17 million U.S. adults have been diagnosed with ADHD but waiting periods to see a specialist often exceed six months. Mentavi’s online, asynchronous platform offers a much-needed solution: some 46% of U.S. adults with ADHD already use telehealth, meaning millions more can benefit from online access to diagnosis and treatment as warranted.

Mentavi’s online evaluation system provides people with an easily accessible and validated means of receiving a mental health diagnosis from a licensed provider. The evaluation has been developed from more than a dozen modern and widely accepted screening instruments and allows for the diagnosis of many mental health conditions, including ADHD.

Mentavi’s clinician-reviewed process delivers timely, evidence-based evaluations that meet the highest standards of clinical credibility. This approach embodies Mentavi Health’s mission: ensuring broad access to accurate, efficient, and evidence-based mental health assessments, grounded in trust and validation.

For more information, visit Mentavi Health or ADHD Online.

*The Mentavi Health Diagnostic Evaluation is clinically validated for the diagnosis of ADHD in adults. Study results were published in the Journal of Clinical Psychiatry on September 8, 2025 (J Clin Psychiatry 2025;86(3):25m15846; DOI:10.4088/JCP.25m15846).

Media Contact:
Tim Cox, ZingPR for Mentavi Health
tim@zingpr.com

About Mentavi Health and ADHD Online
Established as ADHD Online in 2018, Mentavi Health has evolved to encompass a broader range of mental health services. With the mission to make high-quality ADHD assessments accessible to all, Mentavi has grown to address not only ADHD but also the most common related mental health conditions. The nationwide Mentavi Diagnostic Evaluation and various treatment options showcase the company’s commitment to providing comprehensive, accessible, and compliant online mental health care, grounded in clinical validation and trust. For more information, visit mentavi.com.

Source: Mentavi Health

GRAND RAPIDS, Mich., September 11, 2025 — Mentavi Health announced that its landmark, real-world validation study of the Mentavi Diagnostic Evaluation has been published in the peer-reviewed Journal of Clinical Psychiatry (JCP), a widely read and respected journal. The open-access article demonstrates that Mentavi’s asynchronous, online evaluation is as accurate as a traditional face-to-face clinical interview in the diagnosis of attention-deficit / hyperactivity disorder (ADHD) in adults and provides the first peer-reviewed evidence base for a fully digital diagnostic pathway for adult ADHD. The article posted on Psychiatrist.com at 8:00 am Central time on September 8, 2025 (see link and DOI below).

Key findings from the study¹

• n = 345 adults seeking web-based ADHD assessment (predominantly female; mean age = 35).
• Sensitivity = 80.6% and Positive Predictive Value = 94.9%
• False-positive rate = 12% versus 56% for the in-person clinical interview, indicating the online tool is accurate in diagnosing ADHD in adults
• Note: the full article is freely available via JCP (DOI below).

Executive comments

“Publication in a top-tier peer-review journal moves this evidence base forward, for our diagnostic evaluation specifically and for telehealth in general,” said Barry K. Herman, MD, MMM, Chief Medical Officer at Mentavi Health and first author of the paper. “The study shows that an online ADHD diagnosis can be accurately assessed asynchronously, closing gaps in care created by specialist shortages and long waitlists.”

“This study shows that online, asynchronous ADHD assessments can match the rigor of traditional interviews while expanding access for adults who face long wait times,” said Andrew J. Cutler, MD, Chief Medical Officer at Neuroscience Education Institute and Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University, and study co-author. “It demonstrates accuracy, reduces concerns about overdiagnosis, and advances evidence-based care for underserved groups.”

“Publication in JCP sets a new standard for evidence-based digital mental health,” added Keith Brophy, CEO of Mentavi Health. “It validates years of work to build the most rigorous online diagnostic platform and expands our mission to remove barriers of access to accurate mental-health assessments.”

Study design

The prospective, real-world observational study compared the Mentavi Diagnostic Evaluation—a self-paced, asynchronous questionnaire interpreted by a doctorate-level psychologist—with a structured face-to-face clinical interview conducted via video. Primary endpoints were sensitivity, specificity, and positive predictive value relative to DSM-5 criteria. The protocol was IRB-approved and powered to detect ≥80 % sensitivity with 95 % confidence.

Clinical and Public-Health Implications

• Pent-up demand: An estimated 17 million American adults have ADHD, yet waiting lists for specialist evaluation can exceed six months.
  
• Telehealth preference: CDC data indicate 46% of U.S. adults with ADHD already use telehealth services. Until now, no online assessment had been validated.
  
• Health-equity impact: Digital, asynchronous tools remove geographic and scheduling barriers, enabling evidence-based diagnosis for rural, underserved, and shift-working populations.
  

Article details (for authors)

• Journal: The Journal of Clinical Psychiatry
• Article title (final): Validity of an Online Assessment of Attention‑Deficit/Hyperactivity Disorder Among a Real‑World Sample of Adults Seeking Web‑Based Mental Health Care
• Byline: Barry K. Herman, MD, MMM; Stephen V. Faraone, PhD; Andrew J. Cutler, MD; Jeffrey H. Newcorn, MD; Emily M. LaFrance, PhD; Michelle Ripper Lewis, BSN, RN; Charles Ruetsch, PhD
• Citation: J Clin Psychiatry. 2025;86(3):25m15846
• DOI: 10.4088/JCP.25m15846
• URL: https://www.psychiatrist.com/jcp/Validity-Online-ADHD-Assessment-Real-World-Sample-Adults-Seeking-Web-Based-Mental-Healthcare

About Mentavi Health

Established as ADHD Online in 2018, Mentavi Health has evolved to encompass a broader range of mental health services. With the mission to make high-quality ADHD assessments accessible to all, Mentavi has grown to address not only ADHD but also the most common related mental health conditions. The nationwide Mentavi Mental Health Diagnostic Evaluation and various treatment options showcase the company’s commitment to providing comprehensive, accessible, compliant online mental health care. For more information, visit mentavi.com.

Media contact

Tim Cox, ZingPR for Mentavi Health
tim@zingpr.com 

¹ Additional statistics, subgroup analyses, and methodological details are available in the open-access article (Journal of Clinical Psychiatry, on September 8, 2025 (J Clin Psychiatry 2025;86(3):25m15846; doi:10.4088/JCP.25m15846).

At Mentavi Health, our goal is to make comprehensive virtual mental health assessments more accessible to patients nationwide, evaluating for and diagnosing ADHD and other conditions such as anxiety, depression, and OCD.

The data from our landmark validation study* for diagnosing ADHD in Adults marks a significant milestone in the evolution of credible, clinical mental health assessment and treatment in the telehealth space.

About the study

With scientific rigor and clinical oversight, we created a study comparing our Diagnostic Evaluation to the current standard of care for ADHD diagnosis of adults, a face-to-face clinical interview by a trained mental health clinician applying DSM-5 criteria.

The study set out to prove that our digital evaluation could deliver the same accuracy as a traditional clinical interview, only in more convenient, widely accessible ways.

Why clinical validation matters

Adult ADHD remains significantly underdiagnosed and untreated due to barriers such as cost, geography, stigma, and clinician shortages, leaving people without answers or support.

While telehealth evaluations address those gaps in diagnosis and treatment, they also garner a fair amount of skepticism. Many remain hesitant over concerns about accuracy and reliability Can an online-only solution really deliver the same results as traditional methods?

Put simply, yes. The results showed that the Mentavi Mental Health Diagnostic Evaluation is as effective as traditional methods in diagnosing ADHD in adults.

Methods and findings

A total of 345 participants were selected from a pool of more than 2,000 adults seeking online ADHD evaluations for a side-by-side comparison between a secure Zoom-based clinical interview with a licensed psychologist and our asynchronous Diagnostic Evaluation.

The findings revealed a strong 78% agreement rate between the two methods, particularly for ADHD positive cases. The study also showed that the Diagnostic Evaluation demonstrated

• A 94.9% Positive Predictive Value (PPV) for ADHD positive cases.
• A false positive rate of 12% versus 56% for the clinical interview.
• A more conservative rate of diagnosis, suggesting overdiagnosis with our Diagnostic Evaluation is not occurring. In cases where a definitive diagnosis was not confirmed, a recommendation for further evaluation was offered.

The future of mental health treatment

Virtual mental health evaluations are not just convenient and accessible — we’ve demonstrated that they’re also credible and accurate. These findings reinforce our belief in and commitment to evidence-based, thoughtfully designed digital tools that not only deliver reliable results but foster more widespread adoption of telehealth solutions.

Partnering for better outcomes

We’re here to help your patients, members, employees, and students thrive. Together, we can continue making the future of mental health care more accessible, affordable, and streamlined for all. 

To learn more about partnership opportunities with Mentavi Health, visit Mentavi.com/contactus.

*Diagnostic evaluation is clinically validated for the diagnosis of ADHD in Adults. Study results presented at the 2025 ADHD World Congress.